首页> 外文期刊>Liver international >miR‐2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2
【24h】

miR‐2392 functions as tumour suppressor and inhibits malignant progression of hepatocellular carcinoma via directly targeting JAG2

机译:miR-2392 作为肿瘤抑制因子发挥作用,通过直接靶向 JAG2 抑制肝细胞癌的恶性进展

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Abstract Background Aims Dysregulation of microRNA (miRNA) expression in various cancers and their vital roles in malignant progression of cancers are well investigated. Our previous studies have analysed miRNAs that promote malignant progression in hepatocellular carcinoma (HCC); this study aims to systematically elucidate the mechanism of metastasis suppressor miRNAs in HCC. Methods High‐throughput RNA sequencing was used to identify anti‐metastatic miRNAs. The relative expression levels of miRNAs were confirmed by qRT‐PCR. The biological functions of miRNAs were detected in vitro and in vivo. Circulating tumour cells (CTCs) were enriched from blood samples of HCC patients and cultured by three‐dimensional (3D) system. Kaplan–Meier and Cox regression were used to analyse the value of potential target mRNAs on overall survival. Results miR‐2392 was significantly down‐regulated in HCC. Overexpression of miR‐2392 suppressed proliferation, clonogenicity, mobility, spheroid formation and maintenance of cancer stem cells (CSC)‐like characteristics in HCC cells. CTCs from HCC patients with lower serum miR‐2392 level had stronger cell spheroid formation ability. A negative correlation between the content of miR‐2392 in serum and the number of CTC spheroids had been found. We identified Jagged2 (JAG2) as a direct target of miR‐2392. miR‐2392 inhibited the expression of JAG2 by targeting 3’‐UTR of JAG2. Down‐regulation of JAG2 inhibited the overexpression effects of miR‐2392 in vitro and in vivo. JAG2 is highly expressed in HCC and is closely related to poor prognosis and survival of patients. Conclusions miR‐2392 may play a role as a tumour suppressor to guide the individualized precise treatment of HCC.
机译:摘要 背景和目的 microRNA(miRNA)在各种癌症中的表达失调及其在癌症恶性进展中的重要作用得到了很好的研究。我们之前的研究分析了促进肝细胞癌 (HCC) 恶性进展的 miRNA;本研究旨在系统阐明肝癌中转移抑制基因miRNA的机制。方法 采用高通量RNA测序技术鉴定抗转移miRNA。通过qRT-PCR确认miRNA的相对表达水平。在体外和体内检测miRNAs的生物学功能。从HCC患者的血液样本中富集循环肿瘤细胞(CTCs),并通过三维(3D)系统进行培养。Kaplan-Meier和Cox回归用于分析潜在靶mRNA对总生存期的价值。结果 miR-2392在HCC中显著下调。miR-2392 的过表达抑制了 HCC 细胞中癌症干细胞 (CSC) 样特性的增殖、克隆性、迁移性、迁移性、球状体形成和维持。血清miR-2392水平较低的HCC患者的CTCs具有更强的细胞球状体形成能力。血清中miR-2392含量与CTC球体数量呈负相关。我们发现 Jagged2 (JAG2) 是 miR-2392 的直接靶标。miR‐2392 通过靶向 JAG2 的 3'-UTR 抑制 JAG2 的表达。JAG2 的下调抑制了 miR-2392 在体外和体内的过表达作用。JAG2在HCC中高表达,与患者的不良预后和生存密切相关。结论 miR-2392可作为肿瘤抑制因子,指导HCC个体化精准治疗。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号